| About | Exhibitors | 97 Speakers | Reviews | Deals |
Excited about the event? Spread the word and invite your network!
Share
The Rare & Genetic Kidney Disease Drug Development Summit is set to return for its 5th year, providing a vital platform for collaboration among experts in the renal landscape. This summit aims to unite leading minds from biopharma, regulatory bodies, academia, and patient advocacy groups to accelerate transformative therapeutics for
...
rare and genetic kidney diseases. With a focus on fostering relationships and networking opportunities, the event promises to be an exclusive gathering of professionals dedicated to advancing efficacious kidney therapies from discovery to patient implementation.
Major players in the field, including Novartis, Vertex, Otsuka, and Regulus, are making significant strides in clinical trials, while innovative companies like Arbor Biotech, Maze Therapeutics, and ProteinQure are exploring cutting-edge novel modalities and technologies in preclinical studies. Attendees will benefit from insights provided by over 25 expert speakers who will cover the entire spectrum of rare renal drug development, from discovery and preclinical stages to clinical development. The summit will feature three dedicated workshops focusing on key topics such as target identification, mechanistic biology, kidney-on-a-chip models, trial design, recruitment and retention strategies, and patient empowerment.
This comprehensive program will address various renal conditions, including FSGS, PKD, Alport Syndrome, and IgAN. Participants will gain access to unique insights into therapeutic developments across the rare renal field, which they can bring back to their teams for actionable learnings and competitive intelligence. Previous attendees have expressed the value of interacting with expert speakers and peers in the rare renal diseases community, highlighting the summit as an exceptional opportunity to align with the latest biopharma and pharma companies on clinical trials and the regulatory landscape. The event will take place at the Wyndham Boston Beacon Hill in Boston, United States, organized by Hanson Wade Limited, and is expected to attract an audience from Canada and the USA.
Major players in the field, including Novartis, Vertex, Otsuka, and Regulus, are making significant strides in clinical trials, while innovative companies like Arbor Biotech, Maze Therapeutics, and ProteinQure are exploring cutting-edge novel modalities and technologies in preclinical studies. Attendees will benefit from insights provided by over 25 expert speakers who will cover the entire spectrum of rare renal drug development, from discovery and preclinical stages to clinical development. The summit will feature three dedicated workshops focusing on key topics such as target identification, mechanistic biology, kidney-on-a-chip models, trial design, recruitment and retention strategies, and patient empowerment.
This comprehensive program will address various renal conditions, including FSGS, PKD, Alport Syndrome, and IgAN. Participants will gain access to unique insights into therapeutic developments across the rare renal field, which they can bring back to their teams for actionable learnings and competitive intelligence. Previous attendees have expressed the value of interacting with expert speakers and peers in the rare renal diseases community, highlighting the summit as an exceptional opportunity to align with the latest biopharma and pharma companies on clinical trials and the regulatory landscape. The event will take place at the Wyndham Boston Beacon Hill in Boston, United States, organized by Hanson Wade Limited, and is expected to attract an audience from Canada and the USA.
Listed In
Excited about the event? Spread the word and invite your network!
Share
Timings09:00 AM-06:00 PM (expected)Not Verified | Entry FeesCheck Official Website |
Estimated Turnout0-300 Delegates Based on previous editions | Event TypeConference |
EditionsSep 2025 Interested+5 more editions Frequency Bi-annual | Official LinksWebsiteContacts Report Error Claim this event |
Organizer Queries about the event?
Ask Organizer
| |
42.361416-71.066598 Venue Map & Directions | |
Near the venue with time to spare? New in town?
Invite others for coffee and plan your day!
Frequently Asked Questions Contact Organizer
Can I get a list of speakers participating in the event?
Can I get a list of exhibitors participating in the event?
Ask More Questions
Write a Review
Add Your Review EditionSep 2025
How would you like to participate in this event?
Visitor
Exhibitor
Speaker
Followers [ Users who have shown interest for this Event ] Join Community Invite
Invite users with similar interest
Dan Cosgrove
Owner
Boston, United States
Ellis Stone
comcast
Boston, United States
billgates
Manager
Boston, United States
Yida Zhao
Sales Manager
Boston, United States
Xu Chen
Cashier Host/Hostess
Boston, United States
Mahmoud Sakr
Pharmacist
Boston, United States
Clare
founder
Boston, United States
Shannon Irwin
Student
Boston, United StatesView More
Speakers
Speaker
Alex Duncan
Associate Director Of Digital Creative Operations, Michael KorsSpeaker
André Weinstock
Director - Research, Alport syndrome Foundation Inc.Speaker
Arjun Channi
Director - Global Regulatory Affairs, SanofiSpeaker
Chris Mix
Executive Vice President – Clinical Development, Vera TherapeuticsSpeaker
Didier Laurens
Chief Executive Officer, Advicenne PharmaSpeaker
Dr Magnus Nicolson MBA FRSM FRSC
Chief Executive Officer, Invizius Limited42.361416-71.066598
Venue Map & Directions
5 Blossom St, Boston, MA 02114
USA
More Events in Boston
| Sep 162025 | Cell & Gene Therapy International Boston, USA |
| Oct 022025 | Boston Venture Capital World Summit Boston, USA |
| Oct 142025 | Meeting of the American Society of Human Genetics Boston, USA |
| Oct 152025 | R&D Innovation & Product Development Summit World Summit Boston, USA |
Sponsors
Natera
Expertise Partner
USA
https://10times.com/hub/medical-pharma-hub
Aug 182025
